CASE REPORT

**Clostridium paraputrificum Bacteremia in an Older Patient with No Predisposing Medical Condition**

Miho Fukui¹, Shunsuke Iwai¹, Ryunosuke Sakamoto¹, Hiroko Takahashi¹, Tsuneo Hayashi¹ and Tsuneaki Kenzaka²

**Abstract:**
We herein report a rare case of *Clostridium paraputrificum* bacteremia in an elderly (88-year-old) man without a predisposing medical condition. Although he had a history of anaerobic bacteremia approximately eight months prior to admission, no gastrointestinal disease was discovered. He was treated with intravenous ampicillin/sulbactam. This case suggests that *C. paraputrificum* bacteremia can result from only minor abnormalities in macroscopically normal mucosal barriers. To our knowledge, this is the first report of *C. paraputrificum* bacteremia in Japan.

**Key words:** *Clostridium paraputrificum*, bacteremia, underlying medical conditions

(Intern Med 56: 3395-3397, 2017)  
(DOI: 10.2169/internalmedicine.8164-16)

**Introduction**

*Clostridium* species are anaerobic Gram-positive rod bacteria that can cause a broad range of invasive infections in humans, including myonecrosis, intra-abdominal infections, and bacteremia. Infection of *Clostridium* species occurs at a rate of 1.8 per 100,000 persons per year. *C. perfringens* (42%), *C. septicum* (14%), *C. ramosum* (9%), *C. clostridioforme* (6%), and *C. difficile* (5%) are the most common cause of bacteremia. In contrast, *C. paraputrificum* has been identified in only 1% of cases (1). *C. paraputrificum* is an unfamiliar, infrequent isolate (2), and therefore, its clinical significance has not been well described.

We herein report a case of bacteremia caused by *C. paraputrificum* in an older patient without any underlying predisposing medical conditions and discuss the clinical importance of *C. paraputrificum*-related bacteremia.

**Case Report**

An 88-year-old man was admitted to our hospital with a fever and rigors that had begun the day before presentation. He had a 10-year history of hypertension, and approximately 8 months prior to the current admission, he had experienced an episode of pyogenic spondylitis caused by *Bacteroides fragilis*, for which he had been treated with intravenous ampicillin/sulbactam (3 g every 6 h) for 7 weeks, followed by oral amoxicillin-clavulanate potassium (500 mg every 8 h) for 8 subsequent weeks.

Upon admission, the following observations were recorded: blood pressure, 125/69 mmHg; pulse rate, 88 beats/min; respiratory rate, 20 breaths/min; and body temperature, 39.4°C. His physical examination findings were unremarkable. No notable abnormal findings were observed on a physical examination of the chest. The patient’s laboratory findings were as follows: white blood cell count, 11,200×10⁹/L (neutrophils, 89%); hemoglobin, 11.1 g/dL; platelets, 121×10⁹/L; C-reactive protein, 5.61 mg/dL; aspartate aminotransferase, 26 U/L; alanine aminotransferase, 15 U/L; lactic dehydrogenase, 257 U/L; blood urea nitrogen, 19.3 mg/dL; creatinine, 0.68 mg/dL; Na, 140 mEq/L; K, 3.8 mEq/L; Cl, 107 mEq/L; blood glucose, 100 mg/dL; and hemoglo-
Table 1. Laboratory Data on Admission.

| Parameter                        | Recorded value | Standard value |
|----------------------------------|----------------|----------------|
| White blood cell count           | 11,200/μL      | 4,500-7,500/μL |
| Neutrophil frequency             | 89%            |                |
| Hemoglobin                       | 11.1 g/dL      | 11.3-15.2 g/dL |
| Hematocrit                       | 33.2%          | 36-45%         |
| Platelet count                   | 12.1×10³/μL    | 13-35×10³/μL   |
| Activated partial thromboplastin time | 28.3 s   | 26.9-38.1 s    |
| Fibrin degradation products      | 10.0 μg/mL     | 2.0-8.0 μg/mL  |
| C-reactive protein               | 5.61 mg/dL     | ≤0.14 mg/dL    |
| Procalcitonin                    | 2.41 ng/mL     | ≤0.05 ng/mL    |
| Total protein                    | 7.5 g/dL       | 6.9-8.4 g/dL   |
| Albumin                          | 3.5 g/dL       | 3.9-5.1 g/dL   |
| Total bilirubin                  | 0.7 mg/dL      | 0.2-1.2 mg/dL  |
| Aspartate aminotransferase       | 26 U/L         | 11-30 U/L      |
| Alanine aminotransferase         | 15 U/L         | 4-30 U/L       |
| Lactate dehydrogenase            | 257 U/L        | 109-216 U/L    |
| Creatine phosphokinase           | 103 U/L        | 40-150 U/L     |
| Blood urea nitrogen              | 19.3 mg/dL     | 8-20 mg/dL     |
| Creatinine                       | 0.68 mg/dL     | 0.63-1.03 mg/dL|
| Sodium                           | 140 mEq/L      | 136-148 mEq/L  |
| Potassium                        | 3.8 mEq/L      | 3.6-5.0 mEq/L  |
| Glucose                          | 100 mg/dL      | 70-109 mg/dL   |
| Hemoglobin A1c                   | 5.4%           | <6.5%          |

Both sets of anaerobic cultures of blood samples obtained at admission yielded positive results on the second day of hospitalization. Gram staining revealed Gram-positive rods (Figure) that were identified on the third day of hospitalization as *C. paraputrificum* by Rapid ID 32A testing (bioMérieux SA, Marcy l’Etoile, France) in our laboratory. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonics, Yokohama, Japan) was used to definitively identify the isolate as *C. paraputrificum*. Based on the results of antimicrobial susceptibility testing (Table 2), the patient was treated with intravenous ampicillin/sulbactam (3 g every 6 h). Antibiotic therapy alleviated the fever, and subsequent blood cultures conducted after two weeks of treatment yielded negative results.

Because the patient had a history of anaerobic bacteremia about eight months prior to admission, he was investigated for any predisposing medical conditions. Contrast-enhanced abdominal CT, gastroscopy, colonoscopy, small intestine capsule endoscopy, and transesophageal echocardiogram yielded no abnormal findings (e.g., colonic malignancy or inflammatory bowel disease). Laboratory findings excluded diabetes mellitus, HIV, and HTLV-1 infection. More than six months after discharge, the patient had not experienced a relapse.

Discussion

Only a few sporadic case reports of *C. paraputrificum* bacteremia have been reported in the literature. To our knowledge, this is the first report of *C. paraputrificum* bacteremia in Japan. Patients who develop *C. paraputrificum* bacteremia very often have underlying conditions that predispose them to infection, such as noncyclic neutropenia (4), alcohol abuse (5), diabetes mellitus (6), sickle cell ane-
malnourishment (7), malignancy (8, 9), and AIDS (2, 3). Clostridial bacteremia, more generally, is also frequently associated with underlying medical conditions such as colonic malignancy, AIDS, hemodialysis, and inflammatory bowel disease (1-3). The rarity of this case involves the lack of a predisposing medical condition for this patient, except for advanced age.

C. paraputrificum comprises part of the human microflora that resides on mucous membranes (10), and mucosal barrier breakdown can result in clostridial bacteremia (1). Although the patient had no gastrointestinal disease, he had suffered from anaerobic bacteremia twice within one year. In this context, the effects of aging on different organ systems, such as reduced homeostatic responses to injury, are pertinent (11). Increased colonic permeability consequent to the age-associated remodeling of intestinal epithelial tight junction proteins might be an important component of gastrointestinal dysfunction (12). The present case report showed that advanced age can be the only risk factor for C. paraputrificum infection.

Conventional Clostridium spp. classification methods rely on multiple microbiological and biochemical characteristics, including Gram stain morphology and carbohydrate fermentation profiles. Recently developed gene-sequencing techniques (e.g., 16S rRNA gene sequencing) have allowed for the identification of Clostridium genus members at the species level (1). Leal et al. reported the availability of susceptibility testing results for 135 of 138 cases of Clostridium spp. bacteremia; in addition, the overall clindamycin resistance rate was high, whereas most and all but one isolate remained susceptible to penicillin and metronidazole, respectively. Only two isolates of C. paraputrificum were identified in the 138 cases of Clostridium species bacteremia, and both were susceptible to penicillin and metronidazole but resistant to clindamycin (1). In another report, some C. paraputrificum isolates exhibited resistance to erythromycin, tetracycline, and penicillin (13). These data suggest that, in patients with suspected clostridial bacteremia, empiric treatment regimens should include metronidazole in order to minimize the risk of treatment failure; furthermore, clindamycin should not be used as an empiric monotherapy. Finally, the prognosis of C. paraputrificum bacteremia remains unclear due to the small number of cases.

In conclusion, we reported a rare case of C. paraputrificum bacteremia in an older patient with no predisposing medical conditions. Further studies are needed to elucidate the disease spectrum, pathogenesis, and risk factors of C. paraputrificum-related invasive infections, including bacteremia.

The authors state that they have no Conflict of Interest (COI).

Table 2. E-test MICs for Clostridium Paraputrificum Isolated from Blood Cultures of This Patient.

| Antibiotic              | MIC (μg/mL) for Clostridium paraputrificum |
|-------------------------|-------------------------------------------|
| Penicillin G            | 0.25                                      |
| Ampicillin              | 0.125                                     |
| Ampicillin/Sulbactam    | <4                                        |
| Cefazidime              | 8                                         |
| Cefepime                | 2                                         |
| Cefmetazole             | <1                                        |
| Flomoxef                | <1                                        |
| Meropenem               | <0.25                                     |
| Imipenem                | 0.5                                       |
| Minocycline             | <0.25                                     |
| Clindamycin             | 0.5                                       |
| Chloromycetin           | 1                                         |
| Piperacillin/Tazobactam | <16                                       |
| Metronidazole           | 2                                         |

MICs: minimum inhibitory concentrations

References
1. Leal J, Gregson DB, Ross T, Church DL, Laupland KB. Epidemiology of Clostridium species bacteremia in Calgary, Canada. 2000-2006. J Infect 57: 198-203, 2008.
2. Shinha T, Hadi C. Clostridium paraputrificum bacteremia associated with colonic necrosis in a patient with AIDS. Case Rep Infect Dis 2015: 312919, 2015.
3. Nerad JL, Pulvirenti JJ. Clostridium paraputrificum bacteremia in a patient with AIDS and Duodenal Kaposi’s sarcoma. Clin Infect Dis 23: 1183-1184, 1996.
4. Shandra WX, Humphrey RL, Stratton LB. Necrotizing enterocolitis associated with Clostridium paraputrificum septicemia. South Med J 81: 283-284, 1988.
5. Nachamkin I, DeBlais GE, Dalton HP. Clostridium paraputrificum bacteremia associated with aspiration pneumonia. South Med J 75: 1023-1024, 1982.
6. Rathbun HK. Clostridial bacteremia without hemolysis. Arch Intern Med 122: 496-501, 1968.
7. Brook I, Gluck RS. Clostridium paraputrificum sepsis in sickle cell anemia. South Med J 73: 1644-1645, 1980.
8. Bodey GP, Rodriguez S, Fainstein V, Elleing LS. Clostridial bacteremia in cancer patients. A 12-year experience. Cancer 67: 1928-1942, 1991.
9. Denamur E, Tumereille E, Lallement PY, Darchais JP, Veyssier P. Clostridium paraputrificum fulminating sepsis and gas gangrene disclosing acute promyelocytic leukemia. LARC Med 4: 236, 1984 (in French).
10. Stark PL, Lee A. Clostridia isolated from the feaces of infants during the first year of life. J Pediatr 103: 362-365, 1982.
11. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14: 141-153, 2014.
12. Tran L, Greenwood-Van Meerveld B. Age-associated remodeling of the intestinal epithelial barrier. J Gerontol A Biol Sci Med Sci 68: 1045-1056, 2013.
13. Cato EP, George WL, Finegold SM. Genus Clostridium Prazmowski 1880. 23. In: Bergey’s Manual of Systematic Bacteriology. Vol. 2. Holt JG, Sneath PHA, Mair NS, Sharpe ME, Eds. Williams & Wilkins, Baltimore, 1986: 1141-1200.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2017 The Japanese Society of Internal Medicine
Intern Med 56: 3395-3397, 2017 DOI: 10.2169/internalmedicine.8164-16